Cefmenoxime Production Cost Reports

The report provides a detailed analysis essential for establishing a cefmenoxime production plant. It encompasses all critical aspects necessary for cefmenoxime production, including the cost of cefmenoxime production, cefmenoxime plant cost, cefmenoxime production costs, and the overall cefmenoxime production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a cefmenoxime production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cefmenoxime is a broad-spectrum cephalosporin antibiotic that finds important applications in the medical and pharmaceutical industries. It is primarily utilised in the treatment of bacterial infections affecting the respiratory tract, urinary tract, skin, soft tissues, and abdominal organs. It finds its main application in managing infections caused by both Gram-positive and Gram-negative bacteria, including strains resistant to older antibiotics. It is mainly used as a drug to combat respiratory tract infections such as pneumonia, bronchitis, and lung abscesses. It is also used in the treatment of skin and soft tissue issues like cellulitis, abscesses, and infected wounds. It also finds its application in the management of urinary tract infections, including cystitis and pyelonephritis, as well as intra-abdominal conditions like peritonitis and appendicitis. It is also used in surgical prophylaxis to prevent postoperative infections.

The market for cefmenoxime is driven by its application as an antibiotic drug that targets bacterial infections effectively, which largely supports its demand in the pharmaceutical industry. Its application as a medication in the treatment of female gynaecologic and obstetric infections also promotes its demand in the medical and pharmaceutical industries. Its application as a valuable antibiotic in clinical practice to treat cystitis and pyelonephritis, along with certain skin conditions, also contributes to its demand in the pharmaceutical industry.

Its demand as an antibiotic agent in addressing bloodstream infections and gynecologic or obstetric infections involving aerobic and anaerobic pathogens significantly drives its market growth. Moreover, innovations in production processes, reliable supplier partnerships, sustainable production practices, and efficient logistics networks play a significant role in shaping industrial cefmenoxime procurement globally. In addition, overall industrial procurement is also influenced by factors such as the cost and availability of raw materials, compliance with strict regulatory standards, and adherence to environmental and quality guidelines.

Raw Material for Cefmenoxime Production

According to the cefmenoxime production plant project report, the major raw materials for cefmenoxime production include 7β-[α-Methoxyimino-α-(2-aminothiazol-4-yl)acetamido]cephalosporanic acid trifluoroacetic acid and dilute ethanol solution.

Production Process of Cefmenoxime

The extensive cefmenoxime production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of cefmenoxime begins with dissolving 7β-[α-Methoxyimino-α-(2-aminothiazol-4-yl)acetamido]cephalosporanic acid trifluoroacetic acid salt in a water-based solution containing 1-methyl-5-mercapto-1H-tetrazole, sodium bicarbonate, and triethylbenzylammonium bromide as a phase transfer catalyst. The mixture is heated at around 60 degree Celsius under a nitrogen atmosphere for several hours to facilitate a reaction, where the mercaptotetrazole group attaches to the 3-position of the cephalosporin core. After cooling, the reaction solution is purified by passing it through an Amberlite XAD-2 resin column, eluting first with water and then with a dilute ethanol solution to isolate the product. The complete process gives sodium 7β-[α-methoxyimino-α-(2-aminothiazol-4-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylate or sodium cefmenoxime as the final product.

Cefmenoxime is a third-generation cephalosporin antibiotic that appears as a white to off-white crystalline powder. The molecular formula of the compound is C16H17N9O5S3, and its molar mass is 511.6 g/mol. It has a density of approximately 1.96 g/cm³. The compound decomposes at its melting point, which is around 174-175 degree Celsius.

It has a density of 1.96 gm/cm3. It is soluble in dimethyl sulfoxide but exhibits limited solubility in water and ethanol. It is generally stored under inert gas (nitrogen or Argon) at 2-8 degree Celsius. The compound is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. It has demonstrated a high rate of efficacy in many types of infections with no severe side effects. However, it is advised to exercise caution while using the compound in patients with coagulation disorders, as it is a cephalosporin containing the methyltetrazole moiety.